Post-LOE growth and pipeline diversification
11 statements on the record across 2 companies, ordered by how much each has said. Every quote is verbatim from its call.
Both AMGN and MRK frame their loss-of-exclusivity periods as manageable transitions rather than growth disruptions. AMGN's Bradway and Griffith point to a decade of mid-single-digit revenue growth and roughly 9% EPS growth even as biosimilar and generic competition hits about 50% of revenues, with Gordon noting settlements now give clearer visibility on biosimilar entry timing skewed toward the back end of the period, and Griffith expecting growth elsewhere to offset the 2025 denosumab patent expiration [m2467, m2468, m2506, m2492]. MRK's Davis and Litchfield emphasize rapid diversification of growth drivers ahead of the KEYTRUDA LOE, with Davis's confidence rising further by 2026 [m2181, m2189, m2431]. The clearest change in commitment is MRK's raised long-term opportunity estimate, now over $70 billion by the mid-2030s, up $20 billion from a year prior and more than double consensus 2028 KEYTRUDA peak revenue, alongside guidance of 4% to 7% (5% to 8% over time) growth and a conservative 30% to 40% QLEX adoption assumption by 2028 ahead of IRA effects in 2029 [m2430, m2460, m2457, m2456]. The companies diverge in framing: AMGN stresses historical resilience amid ongoing price declines, while MRK centers on a forward-looking pipeline valuation shift.
Rob Davis said MRK is well-positioned to navigate the KEYTRUDA LOE period, with Litchfield noting the company was rapidly moving toward a more diversified portfolio of growth drivers. [m2181, m2189] By 2026, Davis raised confidence further, saying meaningful progress bolsters his already high confidence in sustainable growth post KEYTRUDA LOE. [m2431] Davis now sees over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than a year prior and more than double consensus 2028 peak KEYTRUDA revenue of $35 billion. [m2430] Davis guided growth of 4% to 7%, roughly 5% to 8% over time, and continues to assume 30% to 40% QLEX adoption by 2028, a conservative planning assumption given the IRA taking effect in 2029. [m2460, m2457, m2456]
Show the 7 verbatim statements
#m2181 · 2025-04-24 · Rob Davis · STATED
“Thanks to the incredible efforts of our dedicated team and the strong progress we are achieving, we believe that we're well-positioned to successfully navigate through the KEYTRUDA LOE period.”
#m2189 · 2025-04-24 · Caroline Litchfield · STATED
“Our company is rapidly moving towards a future with a more diversified portfolio of growth drivers.”
#m2460 · 2026-02-03 · Robert M. Davis · STATED
“We actually are giving guidance of growth in, I think, the 4% to 7% or roughly 5% to 8% range over time, which actually is pretty strong growth.”
#m2457 · 2026-02-03 · Robert M. Davis · STATED · by 2028
“As we think about the QLEX adoption, we continue to think we are going to see 30% to 40% adopted as you get out to 2028, and we will drive that as high as we can.”
#m2456 · 2026-02-03 · Robert M. Davis · STATED · by 2028/2029
“For planning purposes, we continue to assume 2028 because I think that is a conservative assumption. We will have to see where it goes. And I would also remind you that we do face the IRA as of the beginning of 2029.”
#m2431 · 2026-02-03 · Robert M. Davis · STATED
“While we still have more to do, this meaningful progress further bolsters my already high confidence in our ability to deliver sustainable growth post the KEYTRUDA LOE period.”
#m2430 · 2026-02-03 · Robert M. Davis · STATED · by mid-2030s
“As a result of this progress, we now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago and more than double consensus 2028 peak KEYTRUDA revenue of $35 billion.”
Bradway framed Amgen's strategy as delivering long-term growth despite regulatory change, declining net prices and losses of exclusivity, citing a decade-long track record of mid-single-digit revenue growth and about 9% EPS growth despite biosimilar and generic competition on products representing about 50% of revenues. [m2467, m2468] Gordon added that settlements now give clearer visibility on biosimilar entry timing, with erosion expected to skew toward the back end of the period. [m2506] Griffith stated that growth elsewhere will more than offset declines from the upcoming denosumab patent expiration and continued portfolio price declines in 2025. [m2492]
Show the 4 verbatim statements
#m2468 · 2025-02-04 · Robert Bradway · STATED
“We have a track record of doing just that. If you consider the past decade, we grew revenues above a mid-single-digit percent level and EPS at approximately 9% per year over the period despite facing biosimilar and generic competition across products that accounted for about 50% of our revenues.”
#m2467 · 2025-02-04 · Robert Bradway · STATED
“Looking ahead, our objective is to deliver long-term growth while navigating regulatory and political change, declining net prices and losses of exclusivity.”
#m2506 · 2025-02-04 · Murdo Gordon · STATED
“Well, we have a bit of a clearer understanding on the timing of when biosimilars will enter given the settlements we've reached. So I would agree that the slope of the biosimilar erosion is going to be, by definition of the timing, more towards the back end.”
#m2492 · 2025-02-04 · Peter Griffith · STATED · by 2025
“This growth will more than offset declines due to the upcoming denosumab patent expiration as well as continued price declines across our portfolio in 2025.”
OPEN is an unresolved commitment on the clock; STATED is on the record without a checkable bar and is never counted or scored. Method: methodology.